Share information
253.40 €
+0.56 %
30/03/2026 17:35
+0.56 %
Open
High
Low
Volume
252.50 €
255.70 €
251.60 €
153,590
Latest News
27-Mar-2026
UCB announces new BIMZELX[®] (bimekizumab-bkzx) data at AAD showing durable symptom control throughout three years in hidradenitis suppurativa
27-Mar-2026
UCB presents new BIMZELX[®] (bimekizumab-bkzx) data at AAD demonstrating high rates of durable and complete skin clearance in moderate-to-severe plaque psoriasis
27-Mar-2026
Acquisition of own shares
27-Mar-2026
UCB Annual General Meeting of Shareholders 2026